Breaking News Instant updates and real-time market news.

NKTR

Nektar

$34.06

-1.24 (-3.51%)

16:55
11/10/18
11/10
16:55
11/10/18
16:55

Nektar management to meet with Piper Jaffray

In conjunction with the SITC Annual Meeting 2018, management participates in a dinner meeting being held in Washington, D.C. on November 10 hosted by Piper Jaffray.

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 27

    Nov

NKTR Nektar
$34.06

-1.24 (-3.51%)

11/08/18
HCWC
11/08/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar shares may have bottomed, says H.C. Wainwright
During last night's Q3 corporate update call, Nektar Therapeutics provided clarity on soon to be initiated Phase 3 programs, with a vital expansion cohort in second line non-small cell lung cancer, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While the renal cell carcinoma, bladder, and melanoma studies were telegraphed previously, "clarity was welcome news for the bulls," says Chattopadhyay. However, the analyst adds that RCC and melanoma remain very crowded and that the initiation of triplet studies, if successfully clinically, "would significantly add to the financial toxicity discussion, especially since NKTR-214 is likely to be marketed as a unique medicine." Chattopadhyay thinks the newly defined cohort of approximately 100 second-line NSCLC patients to the ongoing Pivot trial is key to sentiment around the NKTR-214 story during the second half of 2019. He attributes the recent pullback in Nektar shares to disappointment from the preliminary read from the SITC abstract. Nonetheless, with a host of trial initiations and multiple combination updates at disease specific conferences during 2019, the stock may have bottomed, Chattopadhyay writes. However, the analyst says that while the study initiations and data releases should "quell some fears," the data quality "needs a pickup." He keeps a Neutral rating on Nektar with a $47 price target.
11/08/18
JEFF
11/08/18
NO CHANGE
Target $73
JEFF
Buy
Nektar price target lowered to $73 from $103 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Nektar Therapeutics (NKTR) to $73 after reducing his assumptions for NKTR-214 to reflect a potentially prolonged delay in non-small-cell lung carcinoma. The analyst, however, keeps a Buy rating on the shares following the company's Q3 results. He points out that Nektar's partnership with Bristol-Myers (BMY) as well as its other collaborations are ramping up.
11/06/18
PIPR
11/06/18
NO CHANGE
PIPR
Nektar abstract references old 50% ORR, says Piper Jaffray
The regular Society for Immunotherapy of Cancer abstract that provides an update of the first line melanoma patient cohort in the ongoing PIVOT-02 trial testing the combination of Nektar Therapeutics's NKTR-214 plus Opdivo was posted, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that 41 patients were enrolled with 38 evaluable for efficacy and the investigator-assessed objective response rate as of July 12 was 50%. Van Buren says that while is this is what we already knew, it confirms his prior assumption of the 50% response rate floor heading into the Friday afternoon updated data presentation. On Friday, the analyst expects to receive an updated response rate and more details on the quality of response. Finally, no responder has relapsed in this cohort and median duration of response has not been reached, which is promising as we begin to think about the probability of success for the Phase III trial, says the analyst. Shares of Nektar are down 7%, or $2.75, to $37.25 in pre-market trading.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.80

0.96 (0.35%)

13:12
11/16/18
11/16
13:12
11/16/18
13:12
Periodicals
White House says Trump just expressing optimism on trade, CNBC reports »

CNBC's Eamon Javers…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.80

0.96 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.79

0.95 (0.35%)

13:10
11/16/18
11/16
13:10
11/16/18
13:10
Periodicals
White House tells CNBC not to read too much into Trump's trade comments »

Immediately following…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.79

0.95 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:09
11/16/18
11/16
13:09
11/16/18
13:09
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 11/16…

BHGE

Baker Hughes

$23.40

0.11 (0.47%)

13:05
11/16/18
11/16
13:05
11/16/18
13:05
Hot Stocks
Baker Hughes reports U.S. rig count up 1 to 1,082 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 14

    Nov

ECA

Encana

$7.56

-0.19 (-2.45%)

13:05
11/16/18
11/16
13:05
11/16/18
13:05
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$8.03

0.16 (2.03%)

13:00
11/16/18
11/16
13:00
11/16/18
13:00
Recommendations
Syros Pharmaceuticals analyst commentary  »

Syros Phase I dose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.77

0.93 (0.34%)

12:54
11/16/18
11/16
12:54
11/16/18
12:54
General news
Trump says China 'wants to make a deal' on trade »

President Trump said in…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.77

0.93 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$85.27

-1.48 (-1.71%)

12:50
11/16/18
11/16
12:50
11/16/18
12:50
Options
Notable call writing in Paypal as shares drop 2% »

Notable call writing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 18

    Dec

GOOG

Alphabet

$1,051.92

-12.82 (-1.20%)

, GOOGL

Alphabet Class A

$1,057.14

-14.08 (-1.31%)

12:49
11/16/18
11/16
12:49
11/16/18
12:49
Periodicals
Google Cloud CEO to be replaced by former Oracle executive, CNBC reports »

Google (GOOG, GOOGL)…

GOOG

Alphabet

$1,051.92

-12.82 (-1.20%)

GOOGL

Alphabet Class A

$1,057.14

-14.08 (-1.31%)

ORCL

Oracle

$51.16

0.52 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.08

-0.76 (-0.28%)

12:45
11/16/18
11/16
12:45
11/16/18
12:45
General news
Markets bounce higher after Trump comments on China trade talks »

The markets moved higher…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.08

-0.76 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/16/18
11/16
12:45
11/16/18
12:45
General news
Breaking General news story  »

Week of 11/16…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says would like to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says does not want…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$20.54

-0.53 (-2.52%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
Options
4K Jun 22.5 calls on iQiyi trade $3.40 »

4K Jun 22.5 calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$138.09

-5.77 (-4.01%)

12:38
11/16/18
11/16
12:38
11/16/18
12:38
Hot Stocks
Definers says not hired by Facebook for opposition research »

Definers Public Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LYB

LyondellBasell

$94.38

0.95 (1.02%)

, BAK

Braskem

$27.66

0.56 (2.07%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell (LYB) is…

LYB

LyondellBasell

$94.38

0.95 (1.02%)

BAK

Braskem

$27.66

0.56 (2.07%)

PBR

Petrobras

$14.87

0.32 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$68.91

0.24 (0.35%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Options
Call buying in Cognizant Tech as the company hosts an Investor Day Friday »

Call buying in Cognizant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 26

    Nov

  • 02

    Dec

BAK

Braskem

$27.74

0.64 (2.36%)

, LYB

LyondellBasell

$94.44

1.01 (1.08%)

12:26
11/16/18
11/16
12:26
11/16/18
12:26
Hot Stocks
Breaking Hot Stocks news story on Braskem, LyondellBasell »

Braskem up 54c to $27.68…

BAK

Braskem

$27.74

0.64 (2.36%)

LYB

LyondellBasell

$94.44

1.01 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Periodicals
Airbus, Dassault plan to submit bid for early work on new jet, Reuters says »

Airbus and Dassault…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

LYB

LyondellBasell

$94.48

1.05 (1.12%)

12:24
11/16/18
11/16
12:24
11/16/18
12:24
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$54.66

-0.04 (-0.07%)

12:20
11/16/18
11/16
12:20
11/16/18
12:20
Options
Bearish option flow in Materials Sector ETF »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:20
11/16/18
11/16
12:20
11/16/18
12:20
General news
More from Evans: the short-term policy rate is the first instrument »

More from Evans: the…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/16/18
11/16
12:17
11/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/16/18
11/16
12:16
11/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.